



Highlights of This Issue 2009

REVIEW

- 2011** BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics
 Ryan S. Soderquist and Alan Eastman

SMALL MOLECULE THERAPEUTICS

- 2018** ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme
 Allison E. Cherry, Brian R. Haas, Alipi V. Naydenov, Susan Fung, Cong Xu, Katie Swinney, Michael Wagenbach, Jennifer Freeling, David A. Canton, Jonathan Coy, Eric A. Horne, Barry Rickman, Juan Jesus Vicente, John D. Scott, Rodney J.Y. Ho, Denny Liggitt, Linda Wordeman, and Nephi Stella
- 2030** BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
 Simon J. Hogg, Andrea Newbold, Stephin J. Vervoort, Leonie A. Cluse, Benjamin P. Martin, Gareth P. Gregory, Marcus Lefebure, Eva Vidacs, Richard W. Tothill, James E. Bradner, Jake Shortt, and Ricky W. Johnstone
- 2042**  CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
 Holly E. Barker, Radhika Patel, Martin McLaughlin, Ulrike Schick, Shane Zaidi, Christopher M. Nutting, Katie L. Newbold, Shreerang Bhide, and Kevin J. Harrington
- 2055** Acridine Derivatives as Inhibitors of the IRE1 α -XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma
 Dadi Jiang, Arvin B. Tam, Muthuraman Alagappan, Michael P. Hay, Aparna Gupta, Margaret M. Kozak, David E. Solow-Cordero, Pek Y. Lum, Nicholas C. Denko, Amato J. Giaccia, Quynh-Thu Le, Maho Niwa, and Albert C. Koong
- 2066** A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
 Seiji Toriyama, Mano Horinaka, Shusuke Yasuda, Tomoyuki Taniguchi, Yuichi Aono, Toshiya Takamura, Yukako Morioka, Tsuneharu Miki, Osamu Ukimura, and Toshiyuki Sakai

- 2076** $\alpha_v\beta_3$ Integrin-Targeted Radionuclide Therapy with ^{64}Cu -cyclam-RAFT-c-(RGDFK) $_4$
 Zhao-Hui Jin, Takako Furukawa, Mélissa Degardin, Aya Sugyo, Atsushi B. Tsuji, Tomoteru Yamasaki, Kazunori Kawamura, Yasuhisa Fujibayashi, Ming-Rong Zhang, Didier Boturyn, Pascal Dumy, and Tsuneo Saga
- 2086** Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism
 Meiyan Sun, Qunshu Zhang, Xiaoyu Yang, Steven Y. Qian, and Bin Guo
- 2096**  Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
 Wells S. Brown, Li Tan, Andrew Smith, Nathanael S. Gray, and Michael K. Wendt
- 2107** Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer
 Long Chen, Jie Li, Elia Farah, Sukumar Sarkar, Nihal Ahmad, Sanjay Gupta, James Lerner, and Xiaoqi Liu
- 2119** Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
 Omran Abu Aboud, Ching-Hsien Chen, William Senapedis, Erkan Baloglu, Christian Argueta, and Robert H. Weiss

LARGE MOLECULE THERAPEUTICS



- 2130**  A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells
 Martina Schmittnaegel, Eike Hoffmann, Sabine Imhof-Jung, Cornelia Fischer, Georg Drabner, Guy Georges, Christian Klein, and Hendrik Knoetgen
- 2143**  Direct Pharmacological Inhibition of β -Catenin by RNA Interference in Tumors of Diverse Origin
 Shanthy Ganesh, Martin L. Koser, Wendy A. Cyr, Girish R. Chopda, Junyan Tao, Xue Shui, Bo Ying, Dongyu Chen, Purva Pandya, Edmond Chipumuro, Zakir Siddiquee, Kevin Craig, Chengjung Lai, Henryk Dudek, Satdarshan P. Monga, Weimin Wang, Bob D. Brown, and Marc T. Abrams

Table of Contents




- 2155** MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos, Toddy Sewell, Robert Bader, Jeannette Bannink, Ruth A. Chenault, Mollie Daugherty, Maria Dasovich, Hang Fang, Rebecca Gottschalk, John Kumer, Robert E. Miller, Padma Ravikumar, Jennifer Wiens, Paul A. Algate, David Bienvenue, Catherine J. McMahan, Sateesh K. Natarajan, Jane A. Gross, and John W. Blankenship

- 2166** Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of ⁸⁹Zr-Bevacizumab PET Imaging in Brain Tumor Models
Marc H.A. Jansen, Tonny Lagerweij, A. Charlotte P. Sewing, Danielle J. Vugts, Dannis G. van Vuurden, Carla F.M. Molthoff, Viola Caretti, Susanna J.E. Veringa, Naomi Petersen, Angel M. Carcaboso, David P. Noske, W. Peter Vandertop, Pieter Wesseling, Guus A.M.S. van Dongen, Gertjan J.L. Kaspers, and Esther Hulleman

- 2175** Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Mari Iida, Harsh Bahrar, Toni M. Brand, Hannah E. Pearson, John P. Coan, Rachel A. Orbuch, Bailey G. Flanigan, Adam D. Swick, Prashanth J. Prabakaran, Johan Lantto, Ivan D. Horak, Michael Kragh, Ravi Salgia, Randy J. Kimple, and Deric L. Wheeler

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 2187**  Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Soon Young Park, Yuji Piao, Kang Jin Jeong, Jianwen Dong, and John F. de Groot

- 2198** Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
Xianhui Wang, Jason Wong, Christopher J. Sevinsky, Leila Kokabee, Faiza Khan, Yan Sun, and Douglas S. Conklin

- 2209** MiR-548an, Transcriptionally Downregulated by HIF1 α /HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression
Shuai Zhu, Chi He, Shijiang Deng, Xiang Li, Shipeng Cui, Zhu Zeng, Mingliang Liu, Shufeng Zhao, Jingyuan Chen, Yan Jin, Hengyu Chen, Shichang Deng, Yang Liu, Chunyou Wang, and Gang Zhao

- 2220** Alternative Expression and Localization of Profilin 1/VASP^{PS157} and Cofilin 1/VASP^{PS239} Regulates Metastatic Growth and Is Modified by DHA Supplementation
Mehboob Ali, Kathryn Heyob, Naduparambil K. Jacob, and Lynette K. Rogers

- 2232** Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy
Le Li, Hua Chen, Yue Gao, Yong-Wei Wang, Guang-Quan Zhang, Shang-Ha Pan, Liang Ji, Rui Kong, Gang Wang, Yue-Hui Jia, Xue-Wei Bai, and Bei Sun

- 2244** A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Erin M. Bertino, Elizabeth L. McMichael, Xiaokui Mo, Prashant Trikha, Melanie Davis, Bonnie Paul, Michael Grever, William E. Carson, and Gregory A. Otterson

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 2251** A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
Melissa J. LaBonte, Dongyun Yang, Wu Zhang, Peter M. Wilson, Yasir M. Nagarwala, Kevin M. Koch, Colleen Briner, Tomomi Kaneko, Sun-Young Rha, Oleg Gladkov, Susan G. Urba, Dina Sakaeva, Michael J. Pishvaian, Ruey-Kuen Hsieh, Wei-Ping Lee, and Heinz-Josef Lenz

MODELS AND TECHNOLOGIES

- 2259** Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Ilkka Liikanen, Siri Tähtinen, Kilian Guse, Theresia Gutmann, Paula Savola, Minna Oksanen, Anna Kanerva, and Akseli Hemminki


 AC icon indicates Author Choice
For more information please visit www.aacrjournals.org



Table of Contents

ABOUT THE COVER

Recombinant fusion proteins of monoclonal antibodies and major histocompatibility class I complexes are potential therapeutics to increase antigenicity and facilitate elimination of tumor cells by CD8 effector T cells. This work explores novel formats to optimize potency, safety, and technical properties. For details, see the article by Schmittnaegel and colleagues beginning on page 2130.



Molecular Cancer Therapeutics

15 (9)

Mol Cancer Ther 2016;15:2009-2269.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/15/9>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.